Shares in Newron Pharmaceuticals SpA opened on the Swiss Stock Exchange in Zurich at CHF58 (US$48.20) Tuesday, more than 5 percent above its initial public offering price of CHF55 per share. (BioWorld International)
Arpida Ltd. remains on track to file a new drug application in 2007 for its lead compound, iclaprim, which attained the primary endpoint in the first of two Phase III clinical trials by demonstrating statistical non-inferiority to linezolid (Zyvox) in the treatment of complicated skin and skin-structure infection (CSSSi). (BioWorld International)
Arpida Ltd. remains on track to file a new drug application in 2007 for its lead compound, iclaprim, which attained the primary endpoint in the first of two Phase III clinical trials by demonstrating statistical non-inferiority to linezolid (Zyvox) in the treatment of complicated skin and skin-structure infection (CSSSi). (BioWorld International)
